Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Tomoo Kosuge

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109051040, A5109343532. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 17

  1. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Last author DOI 10.1097/sla.0000000000006730↗
  2. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). First author DOI 10.1093/jjco/hyy190↗
  3. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  4. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗
  5. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Co-author DOI 10.1371/journal.pone.0161009↗
  6. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2015.145↗
  7. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  8. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  9. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ctg.2014.5↗
  10. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Co-author DOI 10.1038/bjc.2013.32↗
  11. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055146↗
  12. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  13. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Last author DOI 10.1245/s10434-011-2020-9↗
  14. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. Co-author DOI 10.1371/journal.pone.0046908↗
  15. Total pancreatectomy with en bloc celiac axis resection for a pancreatic adenocarcinoma involving both the gastroduodenal artery and the celiac artery. Last author DOI 10.5754/hge11687↗
  16. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-10-0397↗
  17. [Evidences for adjuvant therapy of resected pancreatic cancer]. Co-author PMID 21971142↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keita Wada · 3 shared papers, 2014–2026 · strength 0.37
  2. Sohei Satoi · 3 shared papers, 2014–2026 · strength 0.37
  3. Masayuki Sho · 3 shared papers, 2014–2026 · strength 0.37
  4. Ippei Matsumoto · 3 shared papers, 2014–2026 · strength 0.37
  5. Michiaki Unno · 3 shared papers, 2014–2026 · strength 0.37
  6. Fuyuhiko Motoi · 3 shared papers, 2014–2026 · strength 0.37
  7. Hideki Ueno · 2 shared papers, 2019–2026 · strength 0.34
  8. Kazuaki Shimada · 8 shared papers, 2012–2016 · strength 0.32
  9. Shinichiro Takahashi · 2 shared papers, 2012–2026 · strength 0.28
  10. Hirochika Toyama · 1 shared paper, 2026 · strength 0.25
  11. Hideyuki Yoshitomi · 1 shared paper, 2026 · strength 0.25
  12. Tsutomu Fujii · 1 shared paper, 2026 · strength 0.25
  13. Takuji Okusaka · 7 shared papers, 2011–2017 · strength 0.24
  14. Nobuyoshi Hiraoka · 5 shared papers, 2013–2016 · strength 0.23
  15. Yoshinori Ino · 4 shared papers, 2013–2016 · strength 0.19
  16. Shoji Nakamori · 5 shared papers, 2011–2017 · strength 0.17
  17. Tatsuya Ioka · 5 shared papers, 2011–2017 · strength 0.17
  18. Naohiro Sata · 5 shared papers, 2011–2017 · strength 0.17
  19. Akihiko Tsuchida · 5 shared papers, 2011–2017 · strength 0.17
  20. Tesshi Yamada · 5 shared papers, 2011–2017 · strength 0.17
  21. Kazufumi Honda · 5 shared papers, 2011–2017 · strength 0.17
  22. Satoshi Nara · 4 shared papers, 2012–2016 · strength 0.15
  23. Minoru Esaki · 4 shared papers, 2012–2016 · strength 0.15
  24. Hiroki Yamaue · 2 shared papers, 2014–2019 · strength 0.12
  25. Goro Honda · 2 shared papers, 2014–2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.